Point Therapeutics Announces Resignation of William Whelan from Board of Directors
January 24 2007 - 7:12AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) today announced that
because of his other commitments and responsibilities, William J.
Whelan, Jr. has resigned from the Company�s Board of Directors. Mr.
Whelan has served on the Board since 1997. �We are very grateful
for Bill�s contributions, advice, and counsel in his 10 years of
service to Point, and I am joined by the other directors in wishing
him very well,� said Don Kiepert, President, Chairman, and CEO of
Point Therapeutics. About Point Therapeutics, Inc.: Point is a
Boston-based biopharmaceutical company which is currently studying
its lead product candidate, talabostat, in two Phase 3 double blind
placebo-controlled trials in non-small cell lung cancer and in a
Phase 2 trial in combination with gemcitabine in metastatic
pancreatic cancer. Point has also studied talabostat in several
Phase 2 trials, including as a single-agent in metastatic melanoma,
in combination with cisplatin in metastatic melanoma and in
combination with rituximab in advanced chronic lymphocytic
leukemia.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles